权威研究：用了司美格鲁肽2年，你的身体会发生这样的变化

Core Viewpoint - The article discusses the long-term efficacy and safety of semaglutide (Wegovy) for weight management in obese adults, highlighting significant weight loss and improvements in metabolic health over a two-year period [4][6][10]. Group 1: Study Overview - STEP 5 is a phase 3b randomized, double-blind, placebo-controlled trial that evaluated the effects of 2.4 mg semaglutide as an adjunct to lifestyle intervention on weight management in 304 obese adults without type 2 diabetes over 104 weeks [5][6]. - The primary endpoint was the percentage change in weight and the proportion of participants achieving a weight loss of ≥5% by week 104 [5]. Group 2: Weight Loss Results - Participants receiving Wegovy experienced a significant weight loss of -15.2% compared to -2.6% in the placebo group by week 104 [7]. - 77.1% of the semaglutide group achieved at least a 5% weight loss, compared to 34.4% in the placebo group [7]. Group 3: Safety and Tolerability - The most common adverse events associated with Wegovy included nausea, diarrhea, vomiting, constipation, and abdominal pain [9]. - The safety profile of Wegovy in the STEP 5 trial was consistent with previous studies, with 5.9% of patients discontinuing treatment due to adverse events [9]. Group 4: Metabolic and Cardiovascular Health Improvements - Significant reductions in waist circumference (-14.4 cm for semaglutide vs. -5.2 cm for placebo) and systolic blood pressure (-5.7 mmHg for semaglutide vs. -1.6 mmHg for placebo) were observed [10]. - Semaglutide also improved various metabolic parameters, including HbA1c, fasting blood glucose, and lipid profiles compared to placebo [10]. Group 5: Importance of Long-term Weight Management - The results of the STEP 5 trial indicate that semaglutide can help obese adults achieve and maintain weight loss over two years, addressing the challenge of weight regain after initial weight loss [9][10].